Technical Analysis for XRTX - Xortx Therapeutics Inc

Grade Last Price % Change Price Change
F 0.650 4.84% 0.030
XRTX closed up 4.84 percent on Friday, March 24, 2023, on 72 percent of normal volume. The bears made the stock sink to a new 52-week low.
Earnings due: Apr 11
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
180 Bearish Setup Bearish Swing Setup 4.84%
Wide Bands Range Expansion 4.84%
Gapped Down Weakness 4.84%
Oversold Stochastic Weakness 4.84%
Jack-in-the-Box Bearish Bearish Swing Setup -7.14%
Stochastic Buy Signal Bullish -7.14%
Narrow Range Bar Range Contraction -7.14%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 3% about 9 hours ago
Up 2% about 9 hours ago
Up 1% about 9 hours ago
Possible NR7 about 10 hours ago
Bearish 180 Entry about 12 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Xortx Therapeutics Inc Description

XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, hypertension, insulin resistance, and diabetic nephropathy. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is headquartered in Vancouver, Canada.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medical Specialties Organ Systems Diabetes Infection Hypertension Kidney Disease

Is XRTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.0
52 Week Low 0.6
Average Volume 21,965
200-Day Moving Average 1.359
50-Day Moving Average 0.832
20-Day Moving Average 0.732
10-Day Moving Average 0.671
Average True Range 0.062
RSI 40.48
ADX 11.19
+DI 17.820
-DI 26.430
Chandelier Exit (Long, 3 ATRs) 0.713
Chandelier Exit (Short, 3 ATRs) 0.787
Upper Bollinger Bands 0.878
Lower Bollinger Band 0.586
Percent B (%b) 0.22
BandWidth 39.918
MACD Line -0.055
MACD Signal Line -0.052
MACD Histogram -0.0031
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.725
Resistance 3 (R3) 0.717 0.683 0.713
Resistance 2 (R2) 0.683 0.664 0.688 0.708
Resistance 1 (R1) 0.667 0.652 0.675 0.675 0.704
Pivot Point 0.633 0.633 0.638 0.638 0.633
Support 1 (S1) 0.617 0.614 0.625 0.625 0.596
Support 2 (S2) 0.583 0.602 0.588 0.592
Support 3 (S3) 0.567 0.583 0.588
Support 4 (S4) 0.575